Skip to main content
Premium Trial:

Request an Annual Quote

Intomics Collaborates with Lundbeck

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danish bioinformatics and systems biology firm Intomics said today that H. Lundbeck will use its research services for data analysis and integration in its drug development process.

Under the agreement, Intomics will provide Lundbeck with data analysis and systems biology expertise, methods, and tools for analyzing and integrating the large amounts of biological data it generates.

Lundbeck develops and markets drugs for treating central nervous system disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, and insomnia.

"With our data-analysis capabilities and Lundbeck's expertise in the central nervous system area, we see a great synergy that has the potential to benefit patients with CNS related disorders," Intomics CEO Thomas Jensen said in a statement.

Financial terms of the agreement were not released.